Tauriga Sciences Inc. Incorporates its New and Improved Label Design for the Upcoming Launch of its Cupuacu Butter Lip Balm Product
NEW YORK, NY–(Marketwired – Jun 16, 2017) – Tauriga Sciences Inc. (OTC PINK: TAUG) (“Tauriga” or “the Company”), a Company engaged in the building of businesses in the life sciences space, has today announced the completion of its new and improved label design and graphics for its Cupuacu Butter lip balm product (HERMAN), taking into account the feedback obtained from potential customers and retailers during the test-marketing phase (January 1, 2017 – April 30, 2017). The final product, which will incorporate this new label design, is expected to be available in the near future. An image of the new label will be uploaded to the Company’s corporate website (www.tauriga.com) within the next few days.
Initially the Company expects that its HERMAN lip balm product, jointly developed with Cleveland, Ohio based cosmetics firm Ice + Jam LLC (“Ice + Jam”), will be available to the public via Tauriga’s corporate website. Subsequent to that, the Company’s marketing strategy is to approach potential retailers of varying sizes as well as locations.
Due to recently announced capital infusion(s), the Company believes that it now has sufficient capital reserves to launch HERMAN to the retail marketplace.
Tauriga’s CEO Seth M. Shaw expressed, “The Company has made the decision to move forward with the launch of its jointly developed Cupuacu Butter lip balm product. During the test marketing phase, the feedback was very positive with respect to the quality and viability of the actual product. The main criticisms were focused on the label design and graphics and that has now been improved and graphically redesigned. The Company looks forward to launching this product while it continues to pursue its other important corporate goals and initiatives.”
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (OTC PINK: TAUG) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company’s previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpractice lawsuit against its predecessor audit firm, for which it’s seeking monetary damages in excess of $4,500,000 USD.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation: expectations, expects, anticipates, believes, hopes, beliefs, plans and objectives regarding the development, use and marketability of products as well as the attainment of certain corporate goals and milestones (i.e. SEC Periodic Filings, Filing of Proxies, etc.). Such forward-looking statements are based on present circumstances and on Tauriga’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which Tauriga has little or no control. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by Tauriga with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.
Tauriga Sciences Inc.
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
cell # (917) 796 9926
fax # (514) 221 3336